再有几天，肖传国即将获得自由。肖传国之案是个冤案，是方舟子、方玄昌和彭剑在一些媒体协助下、用伪造证据和伪报案情的手段煽动社会而迫害正直学者的冤案。面临肖传国即将获得自由，那帮人试图再次煽动社会、否定肖传国科研。此时此刻，自称“放弃美国国籍”而实际上还是美国公民的北大官员饶毅，也入盟加火，先是为方舟子论文造假行为辩护而伪造了所谓学刊“编委会”结论的信件，然后，又支持方舟子等三人的诬告陷害活动、试图用他伪造的所谓项目审核“标准”来否定肖传国的手术科研。

    就在他们在中国媒体上蠢蠢欲动的时候，在美国、经过记录审核、美国卫生部于2011年02月24日更新网站数据，再次充分肯定肖传国的手术科研，继续原定的资助肖某项目的计划。附后是相关网页的内容摘录，请您分享参考。

    在此之前的早些时候，方舟子等人投诉美国官方机构，用伪造证据指控肖传国的手术科研是“造假”。该更新说明，美国官方全部驳回了方某他们的造谣诽谤。根据网友说，在驳回信件中，美国相关机构明确要求方某们看看相关法规规范、搞懂相关条款再提指控。按照惯例，那种驳回实际上就是批评方某等人的指控是“BAD-FAITH”（即无信用可言的和涉嫌诬告陷害的诽谤性指控），只不过讲讲客气而没直接用“BAD-FAITH”去批评方某等人的恶行、而是用“温和”却是“更损”的词语批评他们，即请他们把起码常识搞懂了再说如何指控的事。

    美国卫生部的更新记录提到了肖传国手术科研的逐步走向成功的过程，说明了当前科研阶段的攻研主题，并保持了原定的项目成功与否的审核标准规范。看看那些内容、再做个对比，可以清楚看到，方某三人和饶毅他们对肖传国搞的指控，全都是几个外行不懂装懂、用伪造证据搞造谣诽谤的诬告陷害活动。

    需要说明的是，在美国，类似卫生部直接资助的科研项目的决策以及跟踪监督进展记录和更新记录，都是经过同行评议的，整个过程和内容也是向所有公民公开的。就是说，且不说同行评议和公民公开知情都肯定了肖传国科研，而且，就是有人想“找碴”或“鸡蛋里挑骨头”来批评甚至试图否定该项目，也是随时随地可行的。然而，那样的事情在美国是没发生的，而方某他们的那种企图被全部驳回，这足以说明肖传国科研不但没有任何“造假”事情，而且是经过考验检验而再次获得美国卫生部及同行评议的充分肯定。

    我想，可以说，这是为肖传国即将获得自由的一个最佳欢迎和最佳祝贺

附件：美国卫生部更新记录，再次表明继续资助肖传国的手术科研。（注：这是摘录。对全部详情感兴趣，可用地址连接去阅读原文全文）。

    Nerve Rerouting Treatment for Neurogenic Bladder in Spina Bifida

          This study is not yet open for participant recruitment.

Verified by William Beaumont Hospitals, June 2010 First Received: March 23, 2010 Last Updated: June 4, 2010

    ClinicalTrials.gov processed this record on February 24, 2011

    [www.clinicaltrials.gov]

    Sponsor: William Beaumont Hospitals. Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Information provided by: William Beaumont Hospitals. ClinicalTrials.gov Identifier: NCT01096459 .

    Detailed Description:

    Spina Bifida (a congenital defect of the spinal cord), causes nerve damage and a loss of sensation and muscle function below the waist resulting in bowel and bladder dysfunction. Patients cannot urinate or are constantly wet, and this continues throughout life causing major quality of life and health problems. Clean intermittent catheterization (draining urine from the bladder with a tube) is usually needed to empty the bladder properly. Medications are routinely required to alleviate high urinary tract pressures that can cause irreversible kidney damage, where dialysis or kidney transplant is the only way to sustain life.

    Dr. Xiao, a Chinese urologist, developed a novel procedure to connect a functioning, healthy lumbar spinal nerve to the sacral nerve that controls the bladder. Hundreds of these procedures have been done in China with good results. The end result is the creation of a new reflex where the bladder can be emptied by scratching or stimulating the skin (over the hip or thigh) supplied by that spinal nerve root. He has reported that in 92 SCI patients, 88% regained bladder control within one year after the nerve rerouting surgery and in 110 children with spina bifida, reported success was 87% at one year. However, in China rigorous follow up is challenging, therefore much is still unknown about how the nerves regenerate post surgery, complications and results occurring in the first year in particular, and the potential role that central nervous system remodeling may play in achieving successful outcomes. Beaumont urologists, in collaboration with Dr. Xiao, were the first in the US to perform this surgery on children with spina bifida. Our preliminary data are very promising, and in 9 subjects at 12 months post procedure, 7/9 subjects could void either voluntarily or by stimulating the new reflex mechanism.

    This current project aims to expand upon our pilot experience to conduct a larger and more rigorous study to establish the safety and effectiveness of the proposed somatic-autonomic reflex pathway procedure in gaining bladder and bowel control in patients with spina bifida. We will also collaborate with and train investigators at another site(s) to determine the training needed to achieve similar safety and effectiveness outcomes, and evaluate possible methods to stimulate the new reflex to improve bladder emptying. Achieving the aims outlined in this multicenter proposal will help firmly establish the procedure as safe and effective, and revolutionize the treatment of bladder and bowel dysfunction in patients with spina bifida in the US.

    Eligibility Criteria

    Inclusion Criteria:

    - Male and female patients age 5 and older with spinal dysraphism (ie. myelomeningocele , lipomyelomeningocele, myelocele, meningocele, occulta) with voiding dysfunction on a CIC program for bladder management for at least one year prior to screening. -Atonic or hyperreflexic bladder documented by urodynamic testing during screening. . Documented history of no more than one tethered cord surgery/release in the past; must be > 2 years post tethered cord surgery/release. - Stable neurogenic bladder dysfunction of at least 1 year or more. - Normal renal function (cr<1.5 mg/dl or GFR >75). - Ambulate independently with or without ankle-foot orthotics (AFOs). - Catheterized volume must be at least 50% of total bladder capacity.

    Exclusion Criteria:

    01. History of bladder cancer, augmentation, or radiation; 02. Anatomic outlet obstruction or urethral strictures; 03. History of untreated vesico-ureteric reflux grade 4 or higher documented on screening video UDT; 04. Hydronephrosis grade 3 or higher; 05. Presence of an ileal conduit or supra-pubic catheter drainage; 06. Subjects with an artificial bladder sphincter; 07. Subjects who have had a sling procedure; 08. Subjects who have had the mitrofanoff procedure; 09. Bladder botox injections within last 12 months; 10. Spina Bifida subjects who underwent intrauterine closure of their myelomeningocele; 11. Unable to ambulate independently with or without AFOs; 12. Subject is pregnant; 13. Contraindications to general anesthesia or surgery; 14. Inability to complete follow up visits for 2 years; 15. Inability to complete (

or have parent complete) self administered questionnaires; 16. Subject possesses any other characteristics that, per investigator's judgment, deems them unsuitable (eg increases risk, impairs data collection, etc) for the procedure/study.（直言了）

英文地址：http://www.clinicaltrials.gov/ct2/show/NCT01096459?term=Nerve+Rerouting+Treatment+for+Neurogenic+Bladder+in+Spina+Bifida&rank=1